Playback speed
10 seconds
4-Year MURANO Study Follow-up: PFS and OS Benefits Are Sustained With Time-Limited Venetoclax-Rituximab Compared With Bendamustine-Rituximab in R/R CLL
By
Fred Hutchinson Cancer Center
FEATURING
Mazyar Shadman
By
Fred Hutchinson Cancer Center
FEATURING
Mazyar Shadman
454 views
January 20, 2020
Login to view comments.
Click here to Login